Ark. judge fines J&J and unit $1.2B over Risperdal marketing

04/11/2012 | CNNMoney

An Arkansas judge said Johnson & Johnson and unit Janssen Pharmaceuticals must pay $1.2 billion for violating the state's False Claims and Deceptive Trade Practices acts in regard to marketing antipsychotic Risperdal. The penalty signals that big drugmakers "cannot lie to the FDA, patients and doctors in order to defraud Arkansas taxpayers of our Medicaid dollars," Arkansas Attorney General Dustin McDaniel said. A spokeswoman for Janssen said evidence showed the firms acted legally, and they will appeal.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA